Saudi Journal of Gastroenterology
Home About us Instructions Submission Subscribe Advertise Contact Login    Print this page  Email this page Small font sizeDefault font sizeIncrease font size 
Users Online: 308 


 
LETTER TO THE EDITOR Table of Contents   
Year : 2010  |  Volume : 16  |  Issue : 4  |  Page : 308-309
Considerable use of furazolidone in Iran


1 Department of Bacteriology, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran
2 Department of Internal Medicine, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
3 Department of Internal Medicine and Gastroenterology, S. Orsola Hospital, Massarenti Bologna, Italy

Click here for correspondence address and email

Date of Web Publication24-Sep-2010
 

How to cite this article:
Abadi AB, Taghvaei T, Vaira D. Considerable use of furazolidone in Iran. Saudi J Gastroenterol 2010;16:308-9

How to cite this URL:
Abadi AB, Taghvaei T, Vaira D. Considerable use of furazolidone in Iran. Saudi J Gastroenterol [serial online] 2010 [cited 2019 Nov 12];16:308-9. Available from: http://www.saudijgastro.com/text.asp?2010/16/4/308/70631


Sir,

Recently, we read a paper by Hasan et al.,[1] suggesting that application of furazolidone in combination with amoxicillin and omeprazole and bismuth subcitrate for two weeks can be a good choice for Helicobacter pylori eradication for dyspeptic patients from Yazd, Iran. However, based on our last publication [2] , there are some contradictory findings related to their publication in Saudi Journal of Gastroenterology. Prescribing furazolidone, a new antibiotic for eradication of Helicobacter pylori from the stomach of infected individuals, [3] is still a matter of controversy. Two major topics concerning the widespread use of furazolidone in Iran remain unclear. We have isolated a high rate of resistant strains of H. pylori, as reported in our publication in 2009, [2] which is close to 25% resistance rate for furazolidone. This is high for a new drug in clinical practice. It was expected that furazolidone would not have a high rate of resistance because it has been newly introduced in our country and H. pylori have not been extensively exposed to this antibiotic.

We believe that the Iranian medical community cannot rely on this drug for achieving an effective regimen against H. pylori strains. New data indicating a rising antimicrobial resistance among H. pylori isolates has been seen. This phenomenon has forced us to find new interventions for optimum treatment. Knowing the status of antibiotics resistance to H. pylori can help physicians to determine best treatment of choice against this rogue bacteria. [3] Furthermore, comprehensive follow-up procedures for primary treated patients, [3] especially with drugs such as furazolidone -as a newly proposed treatment- will be helpful for effective eradication of H. pylori.

Second, Hasan et al,[1] used negative rapid urea test (RUT) as confirmation of eradicated infection, a method which has not been recommended by European as well as American guidelines. [4],[5] Results of our new study [data not published] revealed that rising resistance for furazolidone in our H. pylori isolates showed that we are in need of emergency efforts for solving this problem in our country. Until further trials are performed including follow-up with a high sample size for each region and identification of the exact pattern of resistance, we strongly recommend avoiding the use of furazolidone in treatment regimens of H. pylori.

 
   References Top

1.Hasan SR, Vahid V, Reza PM, Roham SR. A short duration furazolidone therapy in combination of amoxicillin, bismuth subcitrate and omeprazole for eradication of Helicobacter pylori. Saudi J Gastroenterol 2010;16:14-8.  Back to cited text no. 1  [PUBMED]  Medknow Journal  
2.Talebi Bezmin Abadi A, Mohabati Mobarez A, Ajami A, Rafiee A, Taghvaei T. Evaluation on antibiotic resistance of H. pylori isolated from patients admitted to tooba medical center, Sari. J Mazand Univ Med Sci 2009;19:26-32.  Back to cited text no. 2      
3.Selgrad M, Malfertheiner P. New strategies for Helicobacter pylori eradication. Curr Opin Pharmacol 2008;8:593-7.  Back to cited text no. 3  [PUBMED]  [FULLTEXT]  
4.Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, et al. Current concepts in the management of Helicobacter pylori infection: The Maastricht III Consensus Report. Gut 2007;56:772-81.  Back to cited text no. 4  [PUBMED]  [FULLTEXT]  
5.Megraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007;20:280-322.  Back to cited text no. 5      

Top
Correspondence Address:
Tarang Taghvaei
Department of Internal Medicine, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari
Iran
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1319-3767.70631

Rights and Permissions



This article has been cited by
1 High correlation of babA 2 -positive strains of Helicobacter pylori with the presence of gastric cancer
Amin Talebi Bezmin Abadi,Tarang Taghvaei,Ashraf Mohabbati Mobarez,Giuseppina Vaira,Dino Vaira
Internal and Emergency Medicine. 2013; 8(6): 497
[Pubmed] | [DOI]
2 Furazolidone-based therapies for Helicobacter pylori infection: A pooled-data analysis
Zullo, A. and Ierardi, E. and Hassan, C. and De Francesco, V.
Saudi Journal of Gastroenterology. 2012; 18(1): 11-17
[Pubmed]



 

Top
 
  Search
 
  
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Email Alert *
    Add to My List *
* Registration required (free)  


    References

 Article Access Statistics
    Viewed1803    
    Printed130    
    Emailed0    
    PDF Downloaded263    
    Comments [Add]    
    Cited by others 2    

Recommend this journal